Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 25, 2014

Key Technologies Highlighted as Late-Breakers at ACC.14

By Dave Fornell, DAIC editor

Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.  

One of the most anticipated therapies on the interventional front is the use of renal denervation to treat drug resistant hypertension. However, its future was called into question recently when Medtronic announced it failed to meet the primary endpoints in its SYMPLICITY HTN-3 U.S. pivotal trial. The results of that trial will be presented at ACC on Saturday. Experts say this is not the end of the story, and additional data might be revealed in another late-breaker with data from the Global SYMPLICITY Registry. 

Also on the interventional front, the NEXT trial is among the first to compare a biodegradable polymer drug-eluting stent (DES) with a durable polymer DES. 

In electrophysiology, the use of cardiac resynchronization therapy (CRT) devices was expanded a few years ago to patients with mild heart failure. One of the late breakers will discuss long-term survival in this CRT population.

In structural heart, three key presentations are featured. The CHOICE Trial will compare self-expanding (Medtronic’s Corevalve) to balloon expandable (Edwards’ Sapien) TAVR devices. Another compares the Corevalve with surgical outcomes in patients deemed high risk for surgery. The final session will share one-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry.

Complete list of ACC late-breaking trials

For information on ACC.14, the official site is accscientificsession.cardiosource.org 

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
Neovasc, Tiara, transcatheter mitral valve, TMVR

The Neovasc Tiara transcatheter mitral valve is currently being tested in U.S. and international clinical trials. 

Feature | Heart Valve Repair| November 12, 2015 | Dave Fornell
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a
Overlay Init